Cargando…

Additional Value of [(18)F]FDG PET or PET/CT for Response Assessment of Patients with Gastrointestinal Stromal Tumor Undergoing Molecular Targeted Therapy: A Meta-Analysis

To assess the additional value of 2-deoxy-2-[(18)F] fluoro-d-glucose ([(18)F]FDG) positron emission tomography (PET) or PET/CT over conventional morphological imaging techniques in the treatment response assessment of gastrointestinal stromal tumor (GIST) to molecular targeted therapy (MTT), we perf...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokoyama, Kota, Tsuchiya, Junichi, Nakamoto, Yuji, Tateishi, Ukihide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000740/
https://www.ncbi.nlm.nih.gov/pubmed/33800310
http://dx.doi.org/10.3390/diagnostics11030475
_version_ 1783671067129151488
author Yokoyama, Kota
Tsuchiya, Junichi
Nakamoto, Yuji
Tateishi, Ukihide
author_facet Yokoyama, Kota
Tsuchiya, Junichi
Nakamoto, Yuji
Tateishi, Ukihide
author_sort Yokoyama, Kota
collection PubMed
description To assess the additional value of 2-deoxy-2-[(18)F] fluoro-d-glucose ([(18)F]FDG) positron emission tomography (PET) or PET/CT over conventional morphological imaging techniques in the treatment response assessment of gastrointestinal stromal tumor (GIST) to molecular targeted therapy (MTT), we performed a meta-analysis of all the available studies to compare the predictive value of [(18)F]FDG PET or PET/CT and conventional imaging techniques for assessing the response to MTT in GIST. We determined the sensitivities and specificities across studies, we calculated the positive and negative likelihood ratios (LR) and made summary receiver operating characteristic curves (SROC) using hierarchical regression models. Pooled analysis included 4 studies comprising 88 patients. The performance characteristics in [(18)F]FDG PET or PET/CT and CT were as follows: sensitivity, 89% (95% confidence interval (CI) 78, 95), 52% (39, 64); specificity, 65% (44, 83), 92% (75, 99); diagnostic odds ratios (DOR), 5.8 (2.0, 16.8 4.9 (1.5, 16.1); positive LR, 1.9 (1.1, 3.4), 3.0 (1.1, 8.1); and negative LR, 0.23 (0.03, 1.6), 0.66 (0.42, 1.0), respectively. In SROC curves, the area under the curve (AUC) was 0.81 (SE, 0.11) and 0.71 (SE, 0.13) and the Q* index was 0.74 and 0.66, respectively. [(18)F]FDG PET/CT had higher sensitivity, while DOR and SROC curves showed better diagnostic performance in [(18)F]FDG PET and PET/CT studies as compared to CT.
format Online
Article
Text
id pubmed-8000740
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80007402021-03-28 Additional Value of [(18)F]FDG PET or PET/CT for Response Assessment of Patients with Gastrointestinal Stromal Tumor Undergoing Molecular Targeted Therapy: A Meta-Analysis Yokoyama, Kota Tsuchiya, Junichi Nakamoto, Yuji Tateishi, Ukihide Diagnostics (Basel) Article To assess the additional value of 2-deoxy-2-[(18)F] fluoro-d-glucose ([(18)F]FDG) positron emission tomography (PET) or PET/CT over conventional morphological imaging techniques in the treatment response assessment of gastrointestinal stromal tumor (GIST) to molecular targeted therapy (MTT), we performed a meta-analysis of all the available studies to compare the predictive value of [(18)F]FDG PET or PET/CT and conventional imaging techniques for assessing the response to MTT in GIST. We determined the sensitivities and specificities across studies, we calculated the positive and negative likelihood ratios (LR) and made summary receiver operating characteristic curves (SROC) using hierarchical regression models. Pooled analysis included 4 studies comprising 88 patients. The performance characteristics in [(18)F]FDG PET or PET/CT and CT were as follows: sensitivity, 89% (95% confidence interval (CI) 78, 95), 52% (39, 64); specificity, 65% (44, 83), 92% (75, 99); diagnostic odds ratios (DOR), 5.8 (2.0, 16.8 4.9 (1.5, 16.1); positive LR, 1.9 (1.1, 3.4), 3.0 (1.1, 8.1); and negative LR, 0.23 (0.03, 1.6), 0.66 (0.42, 1.0), respectively. In SROC curves, the area under the curve (AUC) was 0.81 (SE, 0.11) and 0.71 (SE, 0.13) and the Q* index was 0.74 and 0.66, respectively. [(18)F]FDG PET/CT had higher sensitivity, while DOR and SROC curves showed better diagnostic performance in [(18)F]FDG PET and PET/CT studies as compared to CT. MDPI 2021-03-08 /pmc/articles/PMC8000740/ /pubmed/33800310 http://dx.doi.org/10.3390/diagnostics11030475 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Yokoyama, Kota
Tsuchiya, Junichi
Nakamoto, Yuji
Tateishi, Ukihide
Additional Value of [(18)F]FDG PET or PET/CT for Response Assessment of Patients with Gastrointestinal Stromal Tumor Undergoing Molecular Targeted Therapy: A Meta-Analysis
title Additional Value of [(18)F]FDG PET or PET/CT for Response Assessment of Patients with Gastrointestinal Stromal Tumor Undergoing Molecular Targeted Therapy: A Meta-Analysis
title_full Additional Value of [(18)F]FDG PET or PET/CT for Response Assessment of Patients with Gastrointestinal Stromal Tumor Undergoing Molecular Targeted Therapy: A Meta-Analysis
title_fullStr Additional Value of [(18)F]FDG PET or PET/CT for Response Assessment of Patients with Gastrointestinal Stromal Tumor Undergoing Molecular Targeted Therapy: A Meta-Analysis
title_full_unstemmed Additional Value of [(18)F]FDG PET or PET/CT for Response Assessment of Patients with Gastrointestinal Stromal Tumor Undergoing Molecular Targeted Therapy: A Meta-Analysis
title_short Additional Value of [(18)F]FDG PET or PET/CT for Response Assessment of Patients with Gastrointestinal Stromal Tumor Undergoing Molecular Targeted Therapy: A Meta-Analysis
title_sort additional value of [(18)f]fdg pet or pet/ct for response assessment of patients with gastrointestinal stromal tumor undergoing molecular targeted therapy: a meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000740/
https://www.ncbi.nlm.nih.gov/pubmed/33800310
http://dx.doi.org/10.3390/diagnostics11030475
work_keys_str_mv AT yokoyamakota additionalvalueof18ffdgpetorpetctforresponseassessmentofpatientswithgastrointestinalstromaltumorundergoingmoleculartargetedtherapyametaanalysis
AT tsuchiyajunichi additionalvalueof18ffdgpetorpetctforresponseassessmentofpatientswithgastrointestinalstromaltumorundergoingmoleculartargetedtherapyametaanalysis
AT nakamotoyuji additionalvalueof18ffdgpetorpetctforresponseassessmentofpatientswithgastrointestinalstromaltumorundergoingmoleculartargetedtherapyametaanalysis
AT tateishiukihide additionalvalueof18ffdgpetorpetctforresponseassessmentofpatientswithgastrointestinalstromaltumorundergoingmoleculartargetedtherapyametaanalysis